William Blair Investment Management LLC Acquires 58,203 Shares of Krystal Biotech, Inc. $KRYS

William Blair Investment Management LLC raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 63.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,302 shares of the company’s stock after acquiring an additional 58,203 shares during the quarter. William Blair Investment Management LLC’s holdings in Krystal Biotech were worth $26,356,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of KRYS. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Braidwell LP boosted its holdings in Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares in the last quarter. Norges Bank acquired a new position in Krystal Biotech during the second quarter worth $38,861,000. First Trust Advisors LP raised its holdings in Krystal Biotech by 571.3% during the second quarter. First Trust Advisors LP now owns 222,370 shares of the company’s stock valued at $30,567,000 after buying an additional 189,245 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after buying an additional 128,639 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other news, Director Dino A. Rossi sold 18,950 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the completion of the transaction, the director owned 78,691 shares of the company’s stock, valued at approximately $20,570,614.31. This represents a 19.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 116,611 shares of company stock worth $30,008,839. 13.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on KRYS. Bank of America increased their price objective on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Guggenheim upped their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group increased their price target on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $326.25.

Krystal Biotech Stock Down 6.1%

Shares of KRYS stock opened at $258.81 on Tuesday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $298.30. The firm has a market cap of $7.57 billion, a PE ratio of 37.78 and a beta of 0.49. The stock has a 50 day moving average of $269.18 and a 200-day moving average of $216.10.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.